Glooko has partnered with French pharmaceutical and healthcare company Sanofi to integrate the latter’s SoloSmart device into its Glooko platform.

SoloSmart is a single add-on connected device intended for use with SoloStar and DoubleStar insulin injection pens.

The device captures the data related to insulin dose, date and time of injection and allows for visualisation of the data in the Glooko app.

It allows the patients to share the data with their healthcare professionals for connected care in diabetes management.

Currently, SoloSmart-connected device is not approved in the US.

Sanofi digital healthcare global head Jared Josleyn said: “At Sanofi, we believe that we will deliver value to people living with diabetes by building an ecosystem with local and global partners.

“With Biocorp, SoloSmart’s manufacturer, Glooko, a leading digital health solution that supports patients and health care partners, and local partners, we aim to improve daily management for individuals living with diabetes.

“For 100 years, Sanofi has been at the forefront of managing diabetes. We continue to build on this heritage with a vision and commitment to help transform diabetes care for 537 million people living with diabetes around the world.”

Sanofi will benefit from Glooko’s global footprint of more than 8,000 clinics to enhance access to digital solutions for people with diabetes.

The SoloSmart cap is currently being integrated with the Glooko platform and will gradually roll out across several countries starting later in 2023.

The combined solution will be offered in English and local languages.

Once the integration is completed, SoloStar and DoubleStar pen users are enabled to add the tracking of insulin dosing and timing to the Glooko functionality.

The insulin tracking data can be linked to other important features of the Glooko mobile app like food tracking, exercise metrics, weight, and blood pressure.

Furthermore, the integrated solution will help users to visualise the interrelation between the insulin dose injected and blood glucose values, and create actionable insights.

Glooko CEO Russ Johannesson said: “We are very pleased to announce our partnership with Sanofi, as this agreement represents the first substantial digital health collaboration between our two companies.

“Glooko is the first global diabetes data management platform to launch with SoloSmart, something our team is particularly proud of.

“This will allow us to further expand our global reach aiming to provide best-in-class technologies that can benefit the lives of people with diabetes.”